Michael A. Mussallem - 08 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Chairman & CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 May 2022
Net transactions value
-$2,106,206
Form type
4
Filing time
10 May 2022, 20:55:03 UTC
Previous filing
05 May 2022
Next filing
14 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +56,831 +57% $0.000000 157,353 08 May 2022 Direct F1
transaction EW Common Stock Options Exercise $980,288 +45,050 +29% $21.76 202,403 10 May 2022 Direct F2
transaction EW Common Stock Sale $261,831 -2,724 -1.3% $96.12 199,679 10 May 2022 Direct F2, F3
transaction EW Common Stock Sale $439,027 -4,700 -2.4% $93.41 194,979 10 May 2022 Direct F2, F4
transaction EW Common Stock Sale $1,147,351 -12,028 -6.2% $95.39 182,951 10 May 2022 Direct F2, F5
transaction EW Common Stock Gift $0 -12,500 -6.8% $0.000000 170,451 10 May 2022 Direct
transaction EW Common Stock Sale $1,238,285 -13,098 -7.7% $94.54 157,353 10 May 2022 Direct F2, F6
transaction EW Common Stock Gift $0 +12,500 +0.37% $0.000000 3,406,517 10 May 2022 By Living Trust
holding EW Common Stock 371,711 08 May 2022 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -56,831 -54% $0.000000 48,712 08 May 2022 Common Stock 56,831 Direct F1
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -45,050 -100% $0.000000* 0 10 May 2022 Common Stock 45,050 $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021.
F3 This transaction was executed in multiple trades at prices ranging from $95.905 to $96.470. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $92.880 to $93.880. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $94.900 to $95.900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $93.890 to $94.890. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.